CancerLinQ LLC, a wholly owned nonprofit of ASCO, has announced key partnerships with the U.S. Food and Drug Administration (FDA) and the National Cancer Institute (NCI). The partnership with FDA will use real-world data from CancerLinQ® to help answer questions about the best use of emerging cancer treatments and inform future regulatory decision-making, and the NCI collaboration will facilitate the exchange of information between CancerLinQ® practices and NCI’s Surveillance, Epidemiology, and End Results (SEER) program.
FDA and CancerLinQ’s project will initially focus on treatments for advanced melanoma and aims to characterize the real-world experience of these patients, inform the clinical use of currently approved therapies, and potentially inform future FDA regulatory review of targeted drugs and immunotherapies. The partnership addresses some of the most important and talked-about advances of the last decade, including the groundbreaking class of immunotherapies known as checkpoint inhibitors and several molecularly targeted therapies.
CancerLinQ® and FDA investigators will explore a variety of issues related to the use of newly approved therapies, including the optimal sequence of treatments, the impact that other health problems have on treatment tolerability and cancer outcomes, and the experience with immunotherapy combinations versus single agents. These findings will be shared with the cancer community to help guide the use of these treatments and inform the development of future clinical trials. FDA may also apply the findings to future drug reviews or labeling refinements.
NCI and CancerLinQ® will incorporate national SEER data on patients diagnosed with cancer into CancerLinQ’s core quality improvement and data-sharing platform. SEER is composed of 18 central cancer registries—covering approximately 30% of the U.S. population—including de-identified population level data on patient demographics, cancer diagnosis, including tumor morphology and stage at diagnosis, first course of treatment, laboratory data, and follow-up for vital status. With integrated access to SEER data in an easy-to-visualize format, CancerLinQ® participants will be able to view and draw comparisons between regional- and national-level SEER data and their own practice data, enhancing the ability to inform clinical care and decision making for their patients.
In a later phase, NCI and CancerLinQ® will pilot a system in selected geographic regions for care providers to quickly and seamlessly upload and transmit their own practice data to the SEER program directly through the CancerLinQ® portal. This data-sharing effort holds the promise to make legally mandated cancer surveillance reporting activities more timely, efficient, and complete, and will enhance the richness of SEER databases for population-level research.
These collaborations are two of many that CancerLinQ® is pursuing with a coalition of partners and thought leaders, including government agencies, medical specialty societies, and life science companies. Through these efforts, CancerLinQ® hopes to learn and share insights that can improve the quality and efficiency of the entire cancer care system.
CancerLinQ® is supported in part through the Conquer Cancer Foundation of ASCO, whose generous donors have helped make the system possible. CancerLinQ® and CancerLinQ Discovery™ are projects of CancerLinQ LLC. For more information on how to participate or partner with CancerLinQ®, visit CancerLinQ.org.